AGP Executive Report

Ebola Alert in Hong Kong: The Centre for Health Protection has activated the city’s Ebola Preparedness and Response Plan, raising the Alert Response Level and tightening airport screening for travellers arriving from Africa after WHO’s Congo/Uganda outbreak warning. Border Health Measures: Port health officers will run temperature checks at flight gates, fast-track symptomatic passengers to isolation in public hospitals, boost traveller education at boundary points, update airlines and the Airport Authority, and notify local doctors and hospitals. Biotech Leadership Move: CK Life Sciences’ Sequencio Therapeutics appointed Emily Tan as Chief Operating Officer to oversee global operations and execution across its development pipeline. Market Mood: India’s Sensex and Nifty opened sharply lower as oil prices surged and West Asia tensions spooked investors. Public Health Research: A new study links early gut microbiome and epigenetic changes to early brain development, with signals tied to autism/ADHD risk. Local Health Watch: Hong Kong also stepped up checks after its first rat hepatitis E case this year, with estate-wide cleaning underway.

HK Health Security: Hong Kong has ramped up airport health screening for travellers arriving from Africa after the WHO declared an Ebola outbreak a public health emergency, while stressing the local risk is currently low. Local Public Health: Authorities are investigating Hong Kong’s first human rat hepatitis E case this year, urging stronger hygiene and rodent control after a 42-year-old with chronic liver disease tested positive. Healthcare Policy & Fraud: The MPF authority says it has flagged suspected forged medical certificates used for early pension withdrawals, after two medical groups reported cases to police. Medical Research: A large study finds no clear link between antidepressant use in pregnancy and autism or ADHD risk in children. Innovation Push: In a bid to become a drug innovation hub, Hong Kong leaders pointed to IP protection, institutions, talent and clinical pathways under the 15th Five-Year Plan. Global Health Tech: Hong Kong’s research community also spotlighted new work on fatty liver drug benefits and a centuries-old baduanjin exercise showing blood-pressure improvements. Cross-border Politics: Trump said Xi is considering releasing a detained pastor, but Jimmy Lai’s case is “a tough one,” keeping attention on rights and health concerns for prisoners.

MPF Crackdown: Hong Kong’s MPF authority says it has flagged suspected fraud tied to forged medical certificates used for early pension withdrawals, after two medical groups reported cases to police—raising concerns about misuse of doctors’ information. Cardiovascular Lifestyle Research: A year-long trial suggests baduanjin, a centuries-old Chinese exercise, can lower blood pressure within three months, with results comparable to some first-line medications. Public Health Alert: Health authorities are investigating Hong Kong’s first rat hepatitis E case this year in a 42-year-old man with chronic liver disease, urging stronger hygiene and rodent control. Digital Wellness: A Central yoga master is rolling out an AI-enhanced yoga app that analyses users’ poses from photos and offers personalised guidance plus a “research assistant” for health-related questions. Community Wellbeing: A local survey highlights loneliness across age groups, estimating 520,000 household members self-isolate. Safety Incident: A 38-year-old motorcyclist died after crashing into a fallen tree in Tai Po; police are following up.

Hong Kong Health Watch: The Centre for Health Protection is investigating the city’s first rat hepatitis E case this year, involving a 42-year-old man with chronic liver disease in Hung Hom, after his May 5 blood test came back positive; authorities say he likely caught it locally and are urging strict hygiene and stronger rodent control. Hospital Safety: Separately, the Department of Health has ordered hospitals to stop using a batch of blood pressure monitoring sets linked to a death at Tuen Mun Hospital, after air bubbles were detected during a heart procedure. Pregnancy Medicine: A massive review in The Lancet Psychiatry finds no causal link between antidepressant use in pregnancy and autism or ADHD, with earlier signals weakening after adjustment for parental mental health and genetics. AI in Care: Malaysia cleared a Korean AI tool for sepsis prediction, while Thailand is moving ahead with an AI-plus-telemedicine eye screening ecosystem. Industry & Trade: India’s April exports jumped 13.6% to about US$80.8b, with pharmaceuticals among key gainers.

Job-market mood shift: A new Gallup poll finds a widening generational split in the US—43% of young adults (15–34) say it’s a good time to find a job locally, versus 64% of those 55+—a change that could deepen political divides. Hong Kong incident: A man in his 70s died after falling from a bus in Tsim Sha Tsui; police classified it as a fatal traffic accident. US–China pressure on Hong Kong cases: Donald Trump said Xi Jinping told him releasing jailed Hong Kong media tycoon Jimmy Lai is “a tough one,” and Trump “did not feel optimistic,” while Xi is said to be considering a detained pastor’s case. Pregnancy mental health update: A Lancet Psychiatry meta-analysis of nearly 25 million pregnancies reports no causal link between antidepressant use in pregnancy and autism or ADHD. Healthcare device safety: Hong Kong ordered hospitals to stop using a batch of blood pressure monitoring sets after an improperly sealed device was linked to a patient death. Disinfection tech: Excimerlight expanded into North America with filter-free 222nm Far-UVC systems aimed at occupied-space pathogen reduction.

Medical Safety Alert: Hong Kong health authorities ordered hospitals to stop using a batch of blood pressure monitoring sets after an improperly sealed device was linked to a rare death during heart surgery at Tuen Mun Hospital, with the supplier told to halt sales while an investigation continues. HK Research & Innovation: The University of Hong Kong is developing a portable, saliva-based AI cancer risk detection device using optical sensing, with larger-scale trials planned in the city. Public Health Watch: The US CDC issued a Level 2 travel warning for Mauritius over life-threatening chikungunya, urging enhanced precautions and vaccination. Mental Health Evidence: A major analysis led by HKU found antidepressants during pregnancy are not tied to higher autism or ADHD risk once key factors are accounted for. Cross-border Health Tech: South Korean firms ROKIT Healthcare and Seers signed Middle East deals to expand AI monitoring and ECG device distribution, including a Seers supply agreement for about 105,000 mobiCARE units. Global Context: Markets stayed jittery as the Trump-Xi summit wrapped up, with oil and inflation fears still weighing on risk appetite.

Pregnancy meds update: A huge University of Hong Kong-led review of 37 studies (25m+ pregnancies) finds antidepressant use during pregnancy shows little to no link to autism or ADHD once researchers account for factors like parental mental health and genetics, pushing back on recent US claims. US–China summit: Trump and Xi wrapped talks in Beijing with agreements tied to Iran nuclear limits and keeping shipping through the Strait of Hormuz open, while Taiwan and political prisoners were notably not front-and-centre in the readouts. HK health innovation: HKU is advancing a portable, saliva-based AI cancer risk detection device moving toward larger-scale trials, aiming for rapid, non-invasive screening. Medtech expansion: South Korea’s ROKIT Healthcare and Seers are signing Middle East deals to scale AI prediction/monitoring and ECG devices. Local safety: A 70-year-old woman died in a Hong Kong flat fire blamed on a faulty air-conditioner, with about 300 residents evacuated. Markets: Asian shares slid as US yields hit one-year highs and inflation fears returned, with Hong Kong’s Hang Seng down.

HK Clinical Safety: Hong Kong’s Hospital Authority opened a probe after a 75-year-old man died at Tuen Mun Hospital following a heart procedure where improperly sealed catheter connections were linked to air bubbles detected during surgery. HK Research & Tech: HKU and a synthetic chemistry lab developed a portable, saliva-based AI optical device aimed at rapid, non-invasive cancer risk detection—poised for larger-scale trials in the city. US–China Human Rights: As Trump meets Xi in Beijing, lawmakers and families are pressing for the release of jailed figures including Jimmy Lai, with Sebastian Lai saying his father’s health has “massively deteriorated” in solitary confinement. Global Health Innovation: Shyld AI raised $13.4M to expand agentic AI that actively runs tasks inside U.S. hospitals, while South Korea’s ROKIT Healthcare and Seers signed Middle East deals to scale AI prediction and ECG monitoring. Market Pulse: India’s Sensex jumped nearly 790 points as volatility eased and buying returned to pharma, telecom and banking.

AI Health Tech in HK: HKU and its synthetic chemistry team are advancing a portable, saliva-based AI optical device for rapid, non-invasive cancer risk detection—aimed at larger-scale trials in Hong Kong. Medtech Expansion (Middle East): South Korean firms ROKIT Healthcare and Seers are pushing AI-enabled monitoring and prediction via Saudi and UAE partners, including chronic kidney disease risk tech and ECG device distribution. Local Research Watch: A new study warns airborne viruses can spread between apartments in multi-family buildings through shared bathroom ventilation systems, after a COVID-19 cluster in Spain. Biotech Deal Momentum: Metis TechBio’s HK IPO raised over HK$2.1b, while BMS and Hengrui sealed a up-to-$15.2b collaboration across 13 early-stage programs. Policy & Health Safety: US lawmakers backed a resolution urging Trump to press for release of jailed political prisoners including Jimmy Lai; in Hong Kong, a self-heating hotpot pack explosion sent 10 students to hospital. Markets: India’s Sensex and Nifty edged up on buying in pharma and banking despite oil and geopolitics.

HKU Cancer Tech: The University of Hong Kong is moving a portable, saliva-based AI cancer risk detection device toward bigger trials, using a non-invasive optical sensing approach. Middle East Medtech Push: South Korean firms ROKIT Healthcare and Seers are expanding via Saudi and UAE partners—CKD prediction AI for LifeHope’s platform and ECG monitoring device supply for PureHealth’s ONE HEALTH. Local Health Incident: Ten Hong Kong students were hurt after a self-heating hotpot pack exploded in class; two were sent to Queen Mary Hospital and eight to Ruttonjee Hospital with tinnitus reported. Drug Regulation Roadmap: Chief Executive John Lee says Hong Kong is on track to set up its own Center for Medical Products Regulation by year-end, aiming to speed up clinical trials and drug approvals. Big Pharma Deal: China’s Hengrui and BMS signed a collaboration worth up to US$15.2bn as Trump heads to Beijing.

HK Health Tech: The University of Hong Kong is moving a portable, saliva-based AI cancer risk test toward bigger trials, using an optical device that reads DNA damage signals from saliva. Medtech Partnerships: South Korea’s ROKIT Healthcare and Seers are pushing into the Middle East—ROKIT’s chronic kidney disease AI is set to plug into Saudi LifeHope’s longevity platform, while Seers will supply about 105,000 mobiCARE ECG monitors to PureHealth’s ONE HEALTH and trial its thynC inpatient monitoring in Abu Dhabi. Oncology Pipeline: Kelun-Biotech (6990.HK) says China’s CDE has cleared an IND for its PD-1 x VEGF bispecific SKB118 (CR-001) for advanced solid tumors. Big Pharma Deal: Bristol Myers Squibb and Hengrui Pharma signed a collaboration worth up to US$15.2b for 13 early-stage oncology/hematology/immunology programs—another sign China remains a key innovation engine as global patent cliffs loom. Policy & Industry: Hong Kong’s leader is doubling down on “embodied AI” as a future industry, positioning the city as a real-world testing ground.

HK AI Push: Hong Kong will set up a new AI+ industry strategy committee, with early focus on life and health tech plus “embodied intelligence,” and plans for an AI R&D institute to start in the second half of the year. Big Pharma Deal: Bristol Myers Squibb and China’s Hengrui Pharma signed a collaboration worth up to $15.2bn for 13 early-stage oncology, immunology and haematology programs, with BMS paying $600m upfront and more tied to milestones. Life Sciences Partnerships: Swedish universities signaled strong interest in deeper ties with Hong Kong on life sciences and biotech, aiming to use local platforms and the upcoming Life and Health Technology Research Institute. Local Health Tech: HKU and partners are developing a portable, saliva-based AI cancer risk detection device for larger-scale trials in Hong Kong. Public Health & Safety: Police arrested two women after a sewage-soaked puppy was found dumped in a bin in Mong Kok and later euthanised; an autopsy is also pending after a man died following a suspected fall from the Spiral Lookout Tower.

Cancer Tech in Hong Kong: HKU is moving a portable, saliva-based AI cancer risk test toward bigger trials, using a non-invasive optical device that reads DNA damage signals from saliva. Medtech Expansion: Korean firms ROKIT Healthcare and Seers are pushing AI prediction/monitoring into the Middle East—ROKIT via Saudi LifeHope for chronic kidney disease prediction, and Seers via a UAE PureHealth unit for large-scale mobiCARE ECG device supply plus an inpatient monitoring pilot in Abu Dhabi. Big Pharma Deal: Jiangsu Hengrui and Bristol Myers Squibb signed collaboration/licensing pacts worth up to $15.2B across early-stage cancer and immunology candidates. Public Health Watch: Hong Kong’s CHP flagged listeria in “siu mei” samples, ordering a restaurant to stop sales and fix hygiene processes. Local Care Context: A Hong Kong couple storm-chasing with children during Typhoon Ragasa avoided criminal conviction via a bind-over settlement. Policy/People: Trump says he’ll raise Jimmy Lai’s release with Xi as US lawmakers push for political prisoners’ priority.

HKU Cancer Tech: The University of Hong Kong and a synthetic chemistry lab have built a portable, saliva-based AI optical device aimed at rapid, non-invasive cancer risk detection—setting up larger trials in Hong Kong. Stroke “Emergency Rescue” Tool: A separate Hong Kong-linked report says a new nasal spray could protect brain cells right after stroke, positioning it as a pre-hospital rescue option. Middle East Medtech Push: South Korean firms ROKIT Healthcare and Seers are expanding via Saudi and UAE partners—chronic kidney disease prediction and ECG monitoring devices are the focus. GSK China Deal: GSK signed with Hong Kong-listed Sino Biopharma to sell its experimental chronic hepatitis B therapy bepirovirsen in mainland China. Local Research Role: A mainland health official urged Hong Kong to take a bigger part in national clinical research and breakthroughs. Market Mood: Stocks and oil are still swinging on US-Iran ceasefire uncertainty, keeping investors cautious.

Key health-related developments (Hong Kong and global)

Hong Kong’s Centre for Health Protection is seeking more information from the World Health Organization about a hantavirus outbreak on the MV Hondius, after three deaths were reported on the cruise and five of eight suspected cases were confirmed by WHO. The authorities said the detected hantaviruses in two confirmed cases belonged to the Andes genotype, described as the only type currently confirmed to have limited human-to-human transmission. Reporting also indicates Hong Kong is ramping up prevention efforts to reduce the risk of the rare disease reaching the city.

Separately, Hong Kong-based research highlighted a different potential respiratory risk: PolyU researchers reported that microbial components in air particulate matter (PM2.5)—including bacterial endotoxins—may trigger inflammatory responses even though they make up an extremely small fraction of PM2.5 mass. The coverage frames this as a “long-overlooked” hazard beyond traditional focus on chemical pollutants like vehicle exhaust and industrial emissions.

Medical/biotech and healthcare industry signals

The most prominent biotech items in the last 12 hours include corporate updates and deal activity: GSK entered a worldwide exclusive license agreement with SiranBio for SA030 (a long-acting siRNA candidate), with milestone payments potentially totaling up to $1.005 billion. Other company-focused coverage included Dogwood Therapeutics’ plan to report Q1 2026 results on May 14 and Rapport Therapeutics’ business update tied to its RAP-219 program (including Phase 2a follow-up data and updated timing expectations for later-stage work).

In addition, INTERPOL reported a major cross-border enforcement operation (Operation Pangea XVIII) that seized 6.42 million doses of unapproved/counterfeit pharmaceuticals worth USD 15.5 million, alongside arrests and disruption of online sales channels—an enforcement theme that aligns with broader concerns about counterfeit medicines.

Hong Kong healthcare-adjacent policy and community coverage

Beyond infectious disease and research, the coverage includes healthcare-adjacent community and system items. For example, Hong Kong’s retail and tourism reporting is extensive in the same window, and there is also a human-interest piece about visually impaired Hongkongers training for the Cigna Healthcare Hyrox Hong Kong 2026 race—showing how health events and accessibility initiatives are being covered alongside clinical topics.

However, the evidence in the most recent 12 hours is sparse on concrete Hong Kong healthcare policy changes; the strongest Hong Kong-specific health items remain the hantavirus outbreak response and the PolyU air-microbe findings.

Context and continuity from earlier in the week

Earlier coverage provides continuity on health and medical risk themes: there were additional reports about Hong Kong researchers developing a “world-first” nasal spray for rapid stroke aid, and broader discussion of healthcare market and insurance dynamics (including Hong Kong private health insurance spending growth). The current day’s emphasis shifts toward outbreak preparedness (hantavirus) and environmental/respiratory risk (microbial PM2.5 components), rather than new treatment breakthroughs—though biotech deal and pipeline updates continue in parallel.

Over the past 12 hours, the most health-relevant items in the Hong Kong–linked coverage were scientific and clinical innovation announcements rather than policy changes. HKU researchers reported developing a nasal spray intended for pre-hospital ischemic stroke treatment, designed to deliver neuroprotective drugs directly to the brain and bypass the blood–brain barrier to reduce brain tissue death before hospital arrival. Separately, a Chinese study reported that an aquatic virus found in shrimp and fish may infect humans’ eyes, with researchers warning that people who handle dissected aquatic animals or eat raw aquatic animals without adequate protection may be at higher risk.

The same 12-hour window also included multiple healthcare-sector business updates, suggesting continued investment momentum in biotech and health services. InnoCare Pharma said China’s NMPA approved an IND to start a clinical trial of its novel CDH17 targeted ADC (ICP-B208), described as having tumor-restricted expression and no approved CDH17 targeted ADCs globally. Lyell Immunopharma reported first-quarter business highlights and financial results, including progress in CAR-T programs (e.g., PiNACLE-H2H dosing commencement). EyePoint also released first-quarter financial results, noting Phase 3 topline data timing for its wet AMD and DME programs. In addition, Sun Life reported a jump in quarterly profit, attributing strength to its Asia business, including Hong Kong protection growth.

Beyond healthcare, the most prominent “macro” thread in the last 12 hours was market sensitivity to Middle East developments and oil prices—factors that can indirectly affect healthcare financing and risk appetite. Coverage described Asian shares rising as oil prices held above $100 amid hopes for reopening the Strait of Hormuz, and another report linked market moves to US-Iran talks and a potential peace deal. While not health-specific, this context helps explain why investor sentiment and capital flows appear active alongside biotech announcements.

From 12 to 24 hours ago, the evidence base becomes more mixed but still shows continuity in health innovation and Hong Kong-related healthcare access. There was mention of Hongkongers paying only HK$240 a year for a leukaemia drug after a system shake-up, and additional Hong Kong nasal-spray coverage echoed the “world-first” prehospital stroke theme. The broader 24 to 72 hours range also reinforces the stroke-spray continuity with another “world-first” nasal spray item, while other healthcare items in that window skew toward corporate deal activity (e.g., UCB acquisition coverage appears in the provided titles, though detailed text is not included here).

Overall, the recent (last 12 hours) coverage is strongest on translational medical innovation (pre-hospital stroke nasal spray; aquatic virus eye infection study) and biopharma pipeline/financial updates (ADC IND approval; CAR-T trial progress; retina drug Phase 3 timing; insurer profit driven by Asia). However, the dataset provided is heavily dominated by non-health headlines, and the most concrete Hong Kong healthcare policy evidence in this excerpt is sparse—so conclusions about system-wide change should be treated cautiously.